Influenza B vaccine lineage selection--an optimized trivalent vaccine.

Autor: Mosterín Höpping A; Department of Zoology, University of Cambridge, Cambridge, United Kingdom., Fonville JM; Department of Zoology, University of Cambridge, Cambridge, United Kingdom; Department of Virology, Erasmus MC, Rotterdam, The Netherlands., Russell CA; Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., James S; Department of Zoology, University of Cambridge, Cambridge, United Kingdom., Smith DJ; Department of Zoology, University of Cambridge, Cambridge, United Kingdom; Department of Virology, Erasmus MC, Rotterdam, The Netherlands. Electronic address: derek.smith@antigenic-cartography.org.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2016 Mar 18; Vol. 34 (13), pp. 1617-1622. Date of Electronic Publication: 2016 Feb 16.
DOI: 10.1016/j.vaccine.2016.01.042
Abstrakt: Epidemics of seasonal influenza viruses cause considerable morbidity and mortality each year. Various types and subtypes of influenza circulate in humans and evolve continuously such that individuals at risk of serious complications need to be vaccinated annually to keep protection up to date with circulating viruses. The influenza vaccine in most parts of the world is a trivalent vaccine, including an antigenically representative virus of recently circulating influenza A/H3N2, A/H1N1, and influenza B viruses. However, since the 1970s influenza B has split into two antigenically distinct lineages, only one of which is represented in the annual trivalent vaccine at any time. We describe a lineage selection strategy that optimizes protection against influenza B using the standard trivalent vaccine as a potentially cost effective alternative to quadrivalent vaccines.
(Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: